Physiological, Pathological Roles and Pharmacology of Insulin Regulated Aminopeptidase

55.9K

views

64

authors

12

articles

Editorial

23 April 2021

Editorial: Physiological, Pathological Roles and Pharmacology of Insulin Regulated Aminopeptidase

Siew Yeen Chai

,

Hugo Gutiérrez-de-Terán

and

Efstratios Stratikos

2,505 views

0 citations

Editors

3

Efstratios Stratikos

National and Kapodistrian University of Athens

Monash University

Hugo Gutiérrez De Teran

Uppsala University

Impact

About

Insulin-regulated aminopeptidase (IRAP, also known as leucyl-cystinyl aminopeptidase, placental leucine aminopeptidase, and oxytocinase, EC 3.4.11.3) is a transmembrane, zinc-dependent aminopeptidase that performs a variety of important biological functions including the generation of antigenic peptides for cross-presentation, regulation of trafficking of glucose transporter type 4, and control of oxytocin levels in pregnancy. IRAP is also a specific binding site for angiotensin IV which, upon binding, serves as a competitive inhibitor of the enzyme. Due to its involvement in several human disease states, IRAP is also an emerging pharmaceutical target.

This Research Topic focuses on recent discoveries on the biology of IRAP as well as on efforts to generate chemical tools to modulate its function for therapeutic interventions.

We welcome expert reviews of aspects of IRAP biology and pharmacology, as well as research papers describing novel findings, on the following sub-topics:
- IRAP structure, function, and enzymology
- Physiological roles of IRAP
- Pathological roles of IRAP
- IRAP as a biomarker of disease
- IRAP inhibitors: discovery, design, and pharmaceutical potential
- IRAP and immunity

Insulin-regulated aminopeptidase (IRAP, also known as leucyl-cystinyl aminopeptidase, placental leucine aminopeptidase, and oxytocinase, EC 3.4.11.3) is a transmembrane, zinc-dependent aminopeptidase that performs a variety of important biological functions including the generation of antigenic peptides for cross-presentation, regulation of trafficking of glucose transporter type 4, and control of oxytocin levels in pregnancy. IRAP is also a specific binding site for angiotensin IV which, upon binding, serves as a competitive inhibitor of the enzyme. Due to its involvement in several human disease states, IRAP is also an emerging pharmaceutical target.

This Research Topic focuses on recent discoveries on the biology of IRAP as well as on efforts to generate chemical tools to modulate its function for therapeutic interventions.

We welcome expert reviews of aspects of IRAP biology and pharmacology, as well as research papers describing novel findings, on the following sub-topics:
- IRAP structure, function, and enzymology
- Physiological roles of IRAP
- Pathological roles of IRAP
- IRAP as a biomarker of disease
- IRAP inhibitors: discovery, design, and pharmaceutical potential
- IRAP and immunity

Download ebook

Share

Editors

Efstratios Stratikos

National and Kapodistrian University of Athens

Monash University

Hugo Gutiérrez De Teran

Uppsala University

Impact

55,911 Total views

42,630 Article views

11,864 Article downloads

1,417 Topic views

Published In

Journal Thumbnail

Frontiers in Molecular Biosciences

Molecular Diagnostics and Therapeutics, Cellular Biochemistry

Journal Thumbnail

Frontiers in Pharmacology

Experimental Pharmacology and Drug Discovery

Journal Thumbnail

Frontiers in Cell and Developmental Biology

Cellular Biochemistry

Journal Thumbnail

Frontiers in Chemistry

Cellular Biochemistry

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic